Sign Out
Chronic heart failure
Adult: Sacubitril 24 mg and valsartan 26 mg tablet
Sacubitril 49 mg and valsartan 51 mg tablet
Sacubitril 97 mg and valsartan 103 mg tablet
In patients with reduced ejection fraction: Initially, 49 mg/51 mg bid; may double the dose after 2-4 weeks to the target maintenance dose of 97 mg/103 mg bid, as tolerated. For patients not currently taking ACE inhibitors or ARBs, or those previously taking low doses of ACE inhibitors or ARBs: Initially, 24 mg/26 mg bid; may increase dose every 2-4 weeks to the target dose of 97 mg/103 mg bid, as tolerated. For patients with systolic blood pressure between 100-110 mmHg, may consider an initial dose of 24 mg/26 mg bid. Dosage recommendations may vary among individual products and between countries (refer to specific product guidelines).
Child: Sacubitril 6 mg and valsartan 6 mg granules in capsule for opening
Sacubitril 15 mg and valsartan 16 mg granules in capsule for opening
In patients with left ventricular systolic dysfunction: ≥1 year Patients weighing <40 kg: Doses are expressed as the combined amount of sacubitril and valsartan: Initially, 1.6 mg/kg bid; increase dose to 2.3 mg/kg bid, then increase to the target dose of 3.1 mg/kg bid. Doses are increased every 2-4 weeks to the target dose, as tolerated. For patients not currently taking ACE inhibitors or ARBs, or those previously taking low doses of ACE inhibitors or ARBs: Initiate at half of the recommended starting dose, then increase the dose to the usual starting dose following the recommended dose titration and adjust dose every 3-4 weeks.
Sacubitril 24 mg and valsartan 26 mg tablet
Sacubitril 49 mg and valsartan 51 mg tablet
Sacubitril 97 mg and valsartan 103 mg tablet
In patients with left ventricular systolic dysfunction: ≥1 year Patients weighing 40-<50 kg: Initially, 24 mg/26 mg bid; increase dose to 49 mg/51 mg bid, then increase to the target dose of 72 mg/78 mg bid. ≥50 kg: Initially, 49 mg/51 mg bid; increase the dose to 72 mg/78 mg bid, then increase to the target dose of 97 mg/103 mg bid. All doses are increased every 2-4 weeks to the target dose, as tolerated. For patients not currently taking ACE inhibitors or ARBs, or those previously taking low doses of ACE inhibitors or ARBs: Initiate at half of the recommended starting dose; for patients weighing 40-<50 kg, an initial dose of 0.8 mg/kg bid is recommended (to be given as granules in capsule). After initiation, increase the dose to the usual starting dose following the recommended dose titration and adjust dose every 3-4 weeks. Dosage and treatment recommendations may vary among individual products and between countries (refer to specific product guidelines).
Sacubitril 49 mg and valsartan 51 mg tablet
Sacubitril 97 mg and valsartan 103 mg tablet
In patients with reduced ejection fraction: Initially, 49 mg/51 mg bid; may double the dose after 2-4 weeks to the target maintenance dose of 97 mg/103 mg bid, as tolerated. For patients not currently taking ACE inhibitors or ARBs, or those previously taking low doses of ACE inhibitors or ARBs: Initially, 24 mg/26 mg bid; may increase dose every 2-4 weeks to the target dose of 97 mg/103 mg bid, as tolerated. For patients with systolic blood pressure between 100-110 mmHg, may consider an initial dose of 24 mg/26 mg bid. Dosage recommendations may vary among individual products and between countries (refer to specific product guidelines).
Child: Sacubitril 6 mg and valsartan 6 mg granules in capsule for opening
Sacubitril 15 mg and valsartan 16 mg granules in capsule for opening
In patients with left ventricular systolic dysfunction: ≥1 year Patients weighing <40 kg: Doses are expressed as the combined amount of sacubitril and valsartan: Initially, 1.6 mg/kg bid; increase dose to 2.3 mg/kg bid, then increase to the target dose of 3.1 mg/kg bid. Doses are increased every 2-4 weeks to the target dose, as tolerated. For patients not currently taking ACE inhibitors or ARBs, or those previously taking low doses of ACE inhibitors or ARBs: Initiate at half of the recommended starting dose, then increase the dose to the usual starting dose following the recommended dose titration and adjust dose every 3-4 weeks.
Sacubitril 24 mg and valsartan 26 mg tablet
Sacubitril 49 mg and valsartan 51 mg tablet
Sacubitril 97 mg and valsartan 103 mg tablet
In patients with left ventricular systolic dysfunction: ≥1 year Patients weighing 40-<50 kg: Initially, 24 mg/26 mg bid; increase dose to 49 mg/51 mg bid, then increase to the target dose of 72 mg/78 mg bid. ≥50 kg: Initially, 49 mg/51 mg bid; increase the dose to 72 mg/78 mg bid, then increase to the target dose of 97 mg/103 mg bid. All doses are increased every 2-4 weeks to the target dose, as tolerated. For patients not currently taking ACE inhibitors or ARBs, or those previously taking low doses of ACE inhibitors or ARBs: Initiate at half of the recommended starting dose; for patients weighing 40-<50 kg, an initial dose of 0.8 mg/kg bid is recommended (to be given as granules in capsule). After initiation, increase the dose to the usual starting dose following the recommended dose titration and adjust dose every 3-4 weeks. Dosage and treatment recommendations may vary among individual products and between countries (refer to specific product guidelines).
